Zacks Investment Research on MSN
Novocure gains FDA approval for Optune Pax to treat pancreatic cancer
Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult ...
Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who ...
(1) Optune Lua includes both active patients in NSCLC and MPM. Worldwide, there were 39 and 32 active MPM patients on therapy as of September 30, 2025 and 2024 and 100 and 1 active NSCLC patient(s) on ...
The "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...
(1) Optune Lua includes both active patients in NSCLC and MPM. Worldwide, there were 43 and 25 active MPM patients on therapy as of June 30, 2025 and 2024 and 94 and 1 active NSCLC patient(s) on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results